SenzaGen (SENZA) Q3 2026 earnings summary

Executive summary

• Q3 revenue rose 7% YoY to SEK 16.3M; EBITDA reached SEK 3.2M and EBIT was positive for the first time at SEK 1.1M.

• The 2030 Growth Plan advanced through operating efficiency and the agreement to acquire Alcyomics, expanding non-animal immunotoxicology testing for drug development.

Financial highlights

• Q3 revenue was SEK 16.3M, up 7% reported and 9% at constant exchange rates; Jan–Sep revenue was SEK 46.5M, up 10% and 12%, respectively.

• Q3 EBITDA was SEK 3.2M vs SEK 0.9M, and EBIT was SEK 1.1M vs SEK -1.0M; Jan–Sep EBIT loss narrowed to SEK 3.1M from SEK 7.6M.

• Q3 gross profit was SEK 12.5M and gross margin 77%, vs SEK 10.0M and 66% YoY; Jan–Sep gross profit was SEK 32.9M with a 71% margin vs 68%.

• Q3 net income was SEK 1.294M vs a SEK 0.661M loss; Jan–Sep net loss narrowed to SEK 2.840M from SEK 7.131M.

• Jan–Sep EBITDA was SEK 3.3M vs a SEK 2.0M loss.

Outlook and guidance

• The 2030 Growth Plan targets profitable growth through commercial expansion, regulatory progress, GARD® platform development and new test methods.

• Alcyomics is expected to accelerate growth and profitability, expanding the serviceable addressable market from USD 0.5bn to USD 0.6bn, equivalent to ~SEK 1bn.

• GARD®skin Medical Device validation is at final stage, with an ISO standard targeted for 2027; GARD®skin Dose-Response is aimed for OECD inclusion in 2027–2028.

• A newly appointed COO will focus on operating efficiency, alignment and realizing synergies across businesses.